Slide 1: Exchange filing cover letter for Q1 FY27 earnings presentation
14th August 2026 Corporate Relationship Department Manager – Listing M/s. BSE Ltd. M/s. National Stock Exchange of India Ltd Mumbai 400 001 Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: - Q1 FY 27 Earnings Presentation Please find enclosed herewith the Earnings Presen
Slide 2: NATCO Pharma Limited Earnings Presentation Q1FY27
NATCO Pharma Limited Earnings Presentation Q1FY27
Slide 3: Disclaimer
Disclaimer THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background information about the
Slide 4: Q1FY27 - Key Business & Consolidated Financial Highlights
Q1FY27 - Key Business & Consolidated Financial Highlights Total Revenue for Q1FY27 stood at INR 7,944 Mn | International Formulations at INR 4,771 Mn | Domestic Formulations Revenue at 1,364 Mn Earnings Before Interest Tax Depreciation and Amortization stood at INR 2,457 Mn and EBITDA Margin at 30.9
Slide 5: Adcock Ingram Holdings
ADCOCK INGRAM HOLDINGS • Established in 1890 as a pharmacy in Krugersdorp, South Africa REVENUE AND NET PROFIT IN US$ Mn and evolved to be one of the biggest pharmaceutical and healthcare companies on the African continent. • Second-largest South African based pharmaceutical company in 592 terms of
Slide 6: Q1FY27 – Segmental Performance
Q1FY27 – Segmental Performance Revenue Breakup (INR Mn) Q1FY27 Q1FY26 Q4FY26 Revenue Breakup (%) – Q1FY27 9.2 8.4 API Revenue 667 526 639 5.1 Pharmaceutical Formulation 17.2 60.1 Formulation – Domestic 1,364 107 1,087 Export formulation Domestic Formulation International Formulations (Incl. profit s
Slide 7: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit & Loss Statement (INR Mn) Q1FY27 Q1FY26 Q4FY26 Total Revenue 7,944 13,906 8,169 Total Expenses (before finance cost and depreciation) 5,487 7,579 6,115 Earnings before interest, tax, depreciation and amortization (EBITDA) 2,457 6,327 2,054 EBITDA margin* (
Slide 8: Key Product Pipeline - USA
Key Product Pipeline - USA Para IVs in the pipeline, with 28 over 20 FTFs (incl. Sole and 17 Approved (either tentative or fully) Shared) Key Sole FTFs (Para IV) in the pipeline Key Para IV products in the pipeline (Filing on NCE-1) date Therapeutic segment/ Therapeutic segment/ Brand Molecule Brand
Slide 9: Our NCE | Cell & Gene Therapy Investments
Our NCE | Cell & Gene Therapy Investments 1 eGenesis 3 Cellogen Therapeutics Invested US$ 8 million in a biotechnology company focused on Invested US$ 2 million focused on advanced cellular xenotransplantation, by developing safe and effective human compatible engineering methods and gene-therapy-ba
Slide 10: Earnings Call Details – Q1 FY27
Earnings Call Details – Q1 FY27 The Earnings call to discuss the operational and financial performance of the company with Mr. Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer, Mr. Amit Parekh, Chief Financial Officer, Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences
Slide 11: Thank You
Thank You Contact: Rajeev Menon – Investor Relations r.menon@natcopharma.co.in / ir@natcopharma.co.in 040-23546208/ Ext: 323 https://twitter.com/pharma_natco https://www.linkedin.com/company/natcopharma NATCO Pharma Limited – Earnings Presentation Q1FY27